BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 52 resultados LastUpdate Última actualización 23/10/2020 [19:14:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 3 nextPage   por página


METHODS OF TREATING GASTROINTESTINAL MOTILITY-RELATED DISORDERS USING VARIANTS AND FUSIONS OF FGF19/FGF21 POLYPEPTIDES

NºPublicación: US2020330555A1 22/10/2020

Solicitante:

NGM BIOPHARMACEUTICALS INC [US]

WO_2018195390_PA

Resumen de: US2020330555A1

Provided herein are methods of treating or preventing gastrointestinal motility-related disorders, treating or preventing constipation or stimulating bowel function, comprising using variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

traducir

TESTING METHOD FOR IRRITABLE BOWEL SYNDROME

NºPublicación: WO2020213732A1 22/10/2020

Solicitante:

CYKINSO INC [JP]

Resumen de: WO2020213732A1

[Problem] To provide a testing method for irritable bowel syndrome. [Solution] A method for providing information on whether a sample obtained from an individual subject or a subject population (user) is associated with irritable bowel syndrome (IBS), wherein the method includes the following steps: (a) a step for generating a data set including a gut microbiota profile in the user, (b) a step for statistical processing of the data set, and (c) a step for providing the results of the processing as an indicator for evaluating whether the sample is a sample associated with IBS.

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020325538A1 15/10/2020

Solicitante:

GENENTECH INC [US]

JP_2020062013_A

Resumen de: US2020325538A1

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

traducir

METHODS OF DIAGNOSING DISEASE

NºPublicación: WO2020201457A1 08/10/2020

Solicitante:

4D PHARMA CORK LTD [IE]

WO_2020201458_A1

Resumen de: WO2020201457A1

The application provides new and improved methods for diagnosing IBS.

traducir

GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS

NºPublicación: US2020318162A1 08/10/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: US2020318162A1

The present invention describes methods of identifying subjects susceptible to fibrosis by targeting bacteria found in intestine-related adipose tissue such as creeping fat, ileal mucosa or related tissue. Based on subject's susceptibility to developing fibrosis, different intervention or treatment options can be used.

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE IN COMPANION ANIMALS

NºPublicación: WO2020205911A1 08/10/2020

Solicitante:

UNIV COLORADO STATE RES FOUND [US]

Resumen de: WO2020205911A1

The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) in companion animals.

traducir

PROCESS FOR DIAGNOSING CHRONIC INFLAMMATORY INTESTINAL DISEASES

NºPublicación: US2020311910A1 01/10/2020

Solicitante:

UNIV NANTES [FR]
CHU DE NANTES CENTRE HOSPITALIER UNIV DE NANTES [FR]
INST NAT SANTE RECH MED [FR]

JP_2019510329_A

Resumen de: US2020311910A1

Some embodiments are directed to a process for quantifying changes in the intestinal mucosa caused by a chronic inflammatory intestinal disease in individuals, an ex vivo process for diagnosing a chronic inflammatory intestinal disease in individuals, and an ex vivo process for the differential diagnosis of Crohn's disease versus ulcerative colitis in individuals.

traducir

USE OF GLYCANS AND GLYCOSYLTRANSFERASES FOR DIAGNOSING/MONITORING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020308644A1 01/10/2020

Solicitante:

CHILDRENS HOSPITAL MED CT [US]

US_2015376696_A1

Resumen de: US2020308644A1

Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

traducir

METHODS FOR EVALUATION OF THE EFFECTIVENESS OF A DRUG OR DRUG CANDIDATE IN TREATING AN INFLAMMATORY BOWEL DISEASE BY USE OF A MULTIPLEXED ASSAY KIT COMPRISING VARIOUS BIOMARKERS

NºPublicación: US2020309790A1 01/10/2020

Solicitante:

MESO SCALE TECHNOLOGIES LLC [US]

US_2018017578_A1

Resumen de: US2020309790A1

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.

traducir

DIAGNOSIS OF CROHN'S DlSEASE AND ULCERATIVE COLITIS

NºPublicación: US2020300866A1 24/09/2020

Solicitante:

FLORA INNOVATION AB [SE]

WO_2019074432_PA

Resumen de: US2020300866A1

The present invention relates to a method for determining if a subject suffers from Crohn's disease or from ulcerative colitis, wherein the method comprises the steps of determining if the subject suffers from inflammatory bowel disease and determining proportion of B-cells which are CD27+ in a sample from the subject. The method may further comprise determining the proportion of CD8+ T-cells which are HLA-DR+ in a sample from the subject. The present invention also relates to biomarkers for use as a marker in the diagnosis of inflammatory bowel disease, Crohn's disease ulcerative colitis. The present invention also relates to a kit for the diagnosis of Crohn's disease and/or ulcerative colitis.

traducir

METHODS OF TREATING DISEASES

NºPublicación: US2020299378A1 24/09/2020

Solicitante:

BOEHRINGER INGELHEIM INT [DE]

JP_2019536756_A

Resumen de: US2020299378A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

METHOD OF DISCRIMINATING BETWEEN INFLAMMATORY BOWEL DISEASE AND GASTROINTESTINAL LYMPHOMA, DISCRIMINATION MARKER AND KIT

NºPublicación: WO2020179887A1 10/09/2020

Solicitante:

UNIV TOKYO [JP]

JP_2020143951_A

Resumen de: WO2020179887A1

The purpose of the present invention is to provide a method for discriminating between inflammatory bowel disease (IBD) and small-cell gastrointestinal lymphoma in carnivorous animals. A method for discriminating between IBD and small-cell gastrointestinal lymphoma in carnivorous animals is provided which involves a step for measuring the expression level in a test animal of an antimicrobial peptide selected from the group consisting of bactericidal/permeability-increasing protein (BPI), lactoferrin, secretory leukocyte peptidase inhibitor (SLPI), lysozyme and canine β-defensin.

traducir

METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO A GUT DYSBIOSIS

NºPublicación: US2020281991A1 10/09/2020

Solicitante:

CRESTOVO HOLDINGS LLC [US]

Resumen de: US2020281991A1

This application provides methods for determining or monitoring the pharmacokinetics (PK) and stable engraftment of live microbial therapeutics, in a subject, through a machine learning model. Disclosed herein is the monitoring and treating of a disorder related to a gut dysbiosis or inflammatory bowel disease in a subject.

traducir

USE OF REELIN AS A BIOMARKER OF INTESTINAL DISEASES (Machine-translation by Google Translate, not legally binding)

NºPublicación: ES2781791A1 07/09/2020

Solicitante:

UNIV SEVILLA [ES]

WO_2020178469_A1

Resumen de: ES2781791A1

Use of reelin as a biomarker of intestinal diseases. Reelin can be used as a single biomarker in the diagnosis and identification of different intestinal pathologies and as a biomarker of the transition from inflammatory bowel disease to tumorigenesis. The inventors have shown that, in response to tissue damage, such as inflammation, the gut responds by increasing reelin expression to strengthen the intestinal barrier and facilitate tissue repair. If inflammation progresses, conditions are established that reduce or suppress reelin expression, where said absence favors the formation of an unfavorable microenvironment that would aggravate inflammation and/or induce tumorigenesis. (Machine-translation by Google Translate, not legally binding)

traducir

ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI

NºPublicación: US2020271650A1 27/08/2020

Solicitante:

CEDARS-SINAI MEDICAL CENTER [US]

US_2019178890_A1

Resumen de: US2020271650A1

The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.

traducir

FECAL SAMPLE, BREATH SAMPLE COLLECTION AND ANALYSIS FOR TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020273540A1 27/08/2020

Solicitante:

VIVANTE HEALTH INC [US]

Resumen de: US2020273540A1

The invention is related to a system for treating irritable bowel syndrome, Crohn's disease, ulcerative colitis (collectively, inflammatory bowel disease, or “IBD”) by determining a number of indicators, including genetic markers, gene expression levels, levels of certain compounds in the gut or feces, hydrogen and/or methane levels, and concentrations of particular bacteria in the gut or feces, and correlating one or more such indicators with symptoms in test subjects with IBD; and correlating diet, drugs, supplements or other therapy, with alleviation of IBD symptoms. The correlations established in the test subjects are confirmed or refuted for individuals suffering IBD, and the treatments established as reducing symptoms are supported through messaging and compliance is verified by monitoring the indicators.

traducir

SYSTEM, COMPOSITION AND METHOD FOR THE DETECTION OF SPECTRAL BIOMARKERS OF A CONDITION AND PATTERNS FROM STOOL SAMPLES

NºPublicación: US2020264098A1 20/08/2020

Solicitante:

CLINICAI INC [US]

WO_2019094341_PA

Resumen de: US2020264098A1

A system, composition and method detect diseases using a method for identifying spectral biomarkers and patterns from stool samples. In one embodiment, the system, composition and method may provide a non-invasive method for detecting colorectal cancer and precancerous polyps comprises subjecting stool samples from cancerous and non-cancerous subjects to hyperspectral spectroscopy and wherein differences in spectra indicates cancer, or assesses risk of development thereof. The system, composition and method may also include a method for identifying spectral biomarkers and patterns from stool samples from cancerous, precancerous and inflammatory bowel disease subjects.

traducir

CCL20 AS A PREDICTOR OF CLINICAL RESPONSE TO IL23-ANTAGONISTS

NºPublicación: US2020262907A1 20/08/2020

Solicitante:

AMGEN INC [US]
MEDIMMUNE LLC [US]

JP_2019508370_A

Resumen de: US2020262907A1

The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

traducir

METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS

NºPublicación: EP3693736A2 12/08/2020

Solicitante:

NOGRA PHARMA LTD [IE]

US_2020032264_A1

Resumen de: EP3693736A2

Methods of treating IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CCL20, IL8, or TNFα levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CCL20, IL8, or TNFα levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CCL20, IL8, or TNFα levels may correlated with IBD remission or decreases in CDAI score.

traducir

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES

NºPublicación: US2020246488A1 06/08/2020

Solicitante:

THE BROAD INSTITUTE INC [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2019018410_PA

Resumen de: US2020246488A1

Embodiments disclosed herein provide methods for modulating intestinal epithelial cell integrity, migration, proliferation, differentiation, maintenance and/or function in which the expression of Cp1orf106 or its protein product are modulated such that the stability of the protein is altered. In certain example embodiments, increasing the stability or preventing a decrease in the stability of Cp1orf106 protein increases the overall integrity of the intestinal epithelium, thereby resulting in a decreased incidence of inflammatory disease. Increased integrity or stability of the epithelium may prevent invasion of migratory cells such as cancer cells.

traducir

IL6 GENE SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF DEVELOPING DRUG-INDUCED LEUKOPENIA AND METHOD FOR PREDICTING RISK OF LEUKOPENIA USING SAME

NºPublicación: WO2020153617A1 30/07/2020

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
SEOUL NAT UNIV HOSPITAL [KR]

KR_20200092864_A

Resumen de: WO2020153617A1

The present invention relates to a composition for predicting the risk of developing leukopenia comprising a single nucleotide polymorphism marker in an IL6 gene and a method for predicting the risk of developing leukopenia using same. As the single nucleotide polymorphism marker in an IL6 gene according to the present invention has a high correlation with the risk of developing leukopenia induced by drugs, in particular thiopurine-based drugs, patients with high susceptibility to leukopenia occurring during thiopurine-based drug treatment from leukemia, Crohn's disease, ulcerative colitis, or organ transplantation etc. can be effectively predicted or diagnosed by using the single nucleotide polymorphism marker at an early stage, and by administering a drug suitable for the patient through such prediction and diagnosis, it is possible to efficiently perform patient-specific treatment that can achieve an optimal treatment effect. Furthermore, the single nucleotide polymorphism marker according to the present invention can be utilized in drug development studies for the treatment of drug-induced leukopenia.

traducir

METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION

NºPublicación: US2020237801A1 30/07/2020

Solicitante:

NOGRA PHARMA LTD [IE]
CELGENE CORP [US]

WO_2017197180_A1

Resumen de: US2020237801A1

Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.

traducir

METHODS FOR MONITORING VEDOLIZUMAB TREATMENT

NºPublicación: US2020241006A1 30/07/2020

Solicitante:

PROMETHEUS BIOSCIENCES INC [US]

KR_20200069333_A

Resumen de: US2020241006A1

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

traducir

Microbial biomarker specific to irritable bowel syndromeIBS and method for predicting risk of irritable bowel syndrome using the same

NºPublicación: KR20200090135A 28/07/2020

Solicitante:

CHUNLAB INC [KR]

Resumen de: KR20200090135A

본 발명은 과민성 대장증후군(IBS)의 진단 또는 위험도 예측을 위한 바이오마커 및 상기 바이오마커를 이용한 IBS의 진단 또는 위험도 예측 방법을 제공한다. 또한 본 발명은 상기 바이오마커를 탐지하기 위한 조성물 및 상기 조성물을 포함하는 과민성 대장증후군의 진단 또는 위험도 예측용 키트를 제공한다. 본 발명이 제공하는 바이오마커는 장내 미생물을 속 또는 종 수준에서 동정함으로써 보다 정확도 높은 과민성 대장증후군의 진단 및 위험도 예측이 가능하다.

traducir

IRRITABLE BOWEL SYNDROME-SPECIFIC MICROBIAL BIOMARKER, AND METHOD FOR PREDICTING RISK OF IRRITABLE BOWEL SYNDROME BY USING SAME

Nº publicación: WO2020149719A2 23/07/2020

Solicitante:

CHUNLAB INC [KR]

Resumen de: WO2020149719A2

The present invention provides a biomarker for the diagnosis or risk prediction of irritable bowel syndrome (IBS), and a method for the diagnosis or risk prediction of IBS by using the biomarker. In addition, the present invention provides a composition for detecting the biomarker, and a kit for diagnosis or risk prediction of irritable bowel syndrome, comprising the composition. The biomarker provided in the present invention identifies intestinal microorganisms at the genus or species level, thereby enabling more accurate diagnosis or risk prediction of irritable bowel syndrome.

traducir

Página1 de 3 nextPage por página

punteroimgVolver